|
1
|
Jaraj D, Höijer J, Widman L, Ahlgren J,
Arnesson LG, Einbeigi Z, Klintman M, Vikhe Patil E, Sund M,
Fredriksson I, et al: Long-term prognostication for 20 114 women
with small and node-negative breast cancer (T1abN0). JNCI Cancer
Spectr. 5:pkaa0842020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Trastuzumab for early-stage,
HER2-positive breast cancer: A meta-analysis of 13 864 women in
seven randomised trials. Lancet Oncol. 22:1139–1150. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart P, Blanchette P, Shah PS, Ye XY,
Boldt RG, Fernandes R, Vandenberg T and Raphael J: Do all patients
with HER2 positive breast cancer require one year of adjuvant
trastuzumab? A systematic review and meta-analysis. Breast.
54:203–210. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen L, Zhou W, Hu X, Yi M, Ye C and Yao
G: Short-duration versus 1-year adjuvant trastuzumab in early HER2
positive breast cancer: A meta-analysis of randomized controlled
trials. Cancer Treat Rev. 75:12–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee HY, Shin IS and Rim CH: Benefits of
adjuvant treatment including trastuzumab in HER2-positive
pT1a-bN0M0 breast cancer: A systematic review and meta-analysis.
Ann Transl Med. 8:1872020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martin M, Holmes FA, Ejlertsen B, Delaloge
S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH,
et al: Neratinib after trastuzumab-based adjuvant therapy in
HER2-positive breast cancer (ExteNET): 5-Year analysis of a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 18:1688–1700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo J, Li Q, Zhang P, Yuan P, Wang J, Ma
F, Fan Y, Cai R, Luo Y, Li Q and Xu B: Trastuzumab plus adjuvant
chemotherapy for human epidermal growth factor receptor 2
(HER2)-positive early-stage breast cancer: A real-world
retrospective study in Chinese patients. Chin J Cancer Res.
31:759–770. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tolaney SM, Guo H, Pernas S, Barry WT,
Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay
M, et al: Seven-year follow-up analysis of adjuvant paclitaxel and
trastuzumab trial for node-negative, human epidermal growth factor
receptor 2-positive breast cancer. J Clin Oncol. 37:1868–1875.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bánkfalvi A, Boecker W and Reiner A:
Comparison of automated and manual determination of HER2 status in
breast cancer for diagnostic use: A comparative methodological
study using the Ventana BenchMark automated staining system and
manual tests. Int J Oncol. 25:929–935. 2004.PubMed/NCBI
|
|
10
|
Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S,
Li Q, Liao N, Liu D, Liu J, et al: National consensus in China on
diagnosis and treatment of patients with advanced breast cancer.
Ann Transl Med. 3:2422015.PubMed/NCBI
|
|
11
|
Breast Cancer Expert Committee of National
Cancer Quality Control Center; Breast Cancer Expert Committee of
China Anti-Cancer Association; Cancer Drug Clinical Research
Committee of China Anti-Cancer Association, . Guidelines for
clinical diagnosis and treatment of advanced breast cancer in China
(2020 edition). Zhonghua Zhong Liu Za Zhi. 42:781–797. 2020.(In
Chinese). PubMed/NCBI
|
|
12
|
World Health Organization (WHO), . Breast
tumors. In: WHO classification of tumors. 5th edition. Vol 2.
International Agency for Research on Cancer; Lyon: 2019, PubMed/NCBI
|
|
13
|
Ali S, Hendry J, Le D, Mondal PK, Sami A,
Chalchal H, Haider K, Ahmed O, El-Gayed A, Wright P, et al:
Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or
bN0M0 breast cancer: A population-based cohort study. Sci Rep.
12:10682022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
National Comprehensive Cancer Network
(NCCN), . Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Breast Cancer. Version 3. NCCN, Plymouth
Meeting; PA: 2023
|
|
15
|
Zhang W, Zhang BL, He JJ, Fan JH, Li J,
Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, et al: Clinicopathological
characteristics and treatment of young women with breast cancer in
China: A nationwide multicenter 10-year retrospective study. Gland
Surg. 10:175–185. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou
T, Ma B, Li H, Liu Q, Ou J, et al: Comparison of
clinicopathological features and treatments between young (≤40
years) and older (>40 years) female breast cancer patients in
West China: A retrospective, epidemiological, multicenter, case
only study. PLoS One. 11:e01523122016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ribnikar D, Ribeiro JM, Pinto D, Sousa B,
Pinto AC, Gomes E, Moser EC, Cardoso MJ and Cardoso F: Breast
cancer under age 40: A different approach. Curr Treat Options
Oncol. 16:162015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang YJ, Oh SJ, Choi H, Cho S, Shin CH,
Kim C, Woo J, Lee J, Park HK, Lee HB, et al: Clinical significance
of HER2 status in T1bN0 breast cancer: A nationwide study from the
Korean breast cancer society. Breast Cancer Res Treat. 186:125–134.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lambertini M, Campbell C, Gelber RD, Viale
G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch
C, et al: Dissecting the effect of hormone receptor status in
patients with HER2-positive early breast cancer: Exploratory
analysis from the ALTTO (BIG 2–06) randomized clinical trial.
Breast Cancer Res Treat. 177:103–114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cameron D, Piccart-Gebhart MJ, Gelber RD,
Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith
I, Gianni L, et al: 11 Years' follow-up of trastuzumab after
adjuvant chemotherapy in HER2-positive early breast cancer: Final
analysis of the HERceptin Adjuvant (HERA) trial. Lancet.
389:1195–1205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Parikh M, Galkin M, Brunson A, Keegan T
and Chew HK: Breast cancer-specific survival in patients with
HER2-positive, node-negative T1a and T1b breast cancer. Cancer
Treat Res Commun. 16:38–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parsons BM, Uprety D, Smith AL, Borgert AJ
and Dietrich LL: A US registry-based assessment of use and impact
of chemotherapy in stage I HER2-positive breast cancer. J Natl
Compr Canc Netw. 16:1311–1320. 2018. View Article : Google Scholar : PubMed/NCBI
|
